Skyrizi
Overview
- Drug Brand Name: Skyrizi
- Active moiety or active ingredient: risankizumab
- Application Number: BLA761105
Skyrizi Cost Review Study Process
Skyrizi was selected for Cost Review by the Board on May 20, 2024.
Relevant Information:
- Presentation of findings from the drugs referred to the Stakeholder Council
- Written comments concerning list of therapeutic alternatives (30 days)
- Comments concerning Board selection of prescription drug products for cost review
The 60 day comment period was posted on May 23, 2024 and comments were accepted until July 22, 2024.
Relevant Information:
Comments received on Skyrizi during the 60 day comment period.
The request for information for Skyrizi was distributed/posted on 5/28/2025. For each prescription drug product under review, the Board may request the following information from: Manufacturer, Health Insurance Carrier, HMO, and MCO, Pharmacy Benefit Managers, and Wholesale Distributors.
Read the archived RFI notice